Pharmacogenetics of treatments for inflammatory bowel disease

Marianna Lucafò, Raffaella Franca, Davide Selvestrel, Debora Curci, Letizia Pugnetti, Giuliana Decorti, Gabriele Stocco

Research output: Contribution to journalReview article

Abstract

Introduction: Inflammatory bowel disease is a chronic inflammation of the gut whose pathogenesis is still unclear. Although no curative therapy is currently available, a number of drugs are used in induction and maintenance therapy; however, for most of these drugs, a high inter-individual variability in response is observed. Among the factors of this variability, genetics plays an important role. Areas covered: This review summarizes the results of pharmacogenetic studies, considering the most important drugs used and in particular aminosalycilates, glucocorticoids, thiopurines, monoclonal antibodies and thalidomide. Most studies used a candidate gene approach, even if significant breakthroughs have been obtained recently from applying genome-wide studies. When available, also investigations considering epigenetics and pharmacogenetic dosing guidelines have been included. Expert opinion: Only for thiopurines, genetic markers identified as predictors of efficacy or adverse events have allowed the development of dosing guidelines. For the other drugs, encouraging results are available and great expectations rely on the study of epigenetics and integration with pharmacokinetic information, especially useful for biologics. However, to improve therapy of IBD patients with these drugs, for implementation in the clinics of pharmacogenetics, informatic clinical decision support systems and training about pharmacogenetics of health providers are needed.

Original languageEnglish
Pages (from-to)1209-1223
Number of pages15
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume14
Issue number12
DOIs
Publication statusPublished - Dec 2 2018

Fingerprint

Pharmacogenetics
Inflammatory Bowel Diseases
Pharmaceutical Preparations
Epigenomics
Genes
Clinical Decision Support Systems
Guidelines
Therapeutics
Informatics
Thalidomide
Pharmacokinetics
Expert Testimony
Decision support systems
Biological Products
Genetic Markers
Glucocorticoids
Monoclonal Antibodies
Health
Genome
Inflammation

Keywords

  • Biologics
  • glucocorticoids
  • inflammatory bowel disease
  • pharmacogenetics
  • thalidomide
  • thiopurines

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Pharmacogenetics of treatments for inflammatory bowel disease. / Lucafò, Marianna; Franca, Raffaella; Selvestrel, Davide; Curci, Debora; Pugnetti, Letizia; Decorti, Giuliana; Stocco, Gabriele.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 14, No. 12, 02.12.2018, p. 1209-1223.

Research output: Contribution to journalReview article

Lucafò, Marianna ; Franca, Raffaella ; Selvestrel, Davide ; Curci, Debora ; Pugnetti, Letizia ; Decorti, Giuliana ; Stocco, Gabriele. / Pharmacogenetics of treatments for inflammatory bowel disease. In: Expert Opinion on Drug Metabolism and Toxicology. 2018 ; Vol. 14, No. 12. pp. 1209-1223.
@article{79a891e5d0c54d8bbdc88502b6f436fc,
title = "Pharmacogenetics of treatments for inflammatory bowel disease",
abstract = "Introduction: Inflammatory bowel disease is a chronic inflammation of the gut whose pathogenesis is still unclear. Although no curative therapy is currently available, a number of drugs are used in induction and maintenance therapy; however, for most of these drugs, a high inter-individual variability in response is observed. Among the factors of this variability, genetics plays an important role. Areas covered: This review summarizes the results of pharmacogenetic studies, considering the most important drugs used and in particular aminosalycilates, glucocorticoids, thiopurines, monoclonal antibodies and thalidomide. Most studies used a candidate gene approach, even if significant breakthroughs have been obtained recently from applying genome-wide studies. When available, also investigations considering epigenetics and pharmacogenetic dosing guidelines have been included. Expert opinion: Only for thiopurines, genetic markers identified as predictors of efficacy or adverse events have allowed the development of dosing guidelines. For the other drugs, encouraging results are available and great expectations rely on the study of epigenetics and integration with pharmacokinetic information, especially useful for biologics. However, to improve therapy of IBD patients with these drugs, for implementation in the clinics of pharmacogenetics, informatic clinical decision support systems and training about pharmacogenetics of health providers are needed.",
keywords = "Biologics, glucocorticoids, inflammatory bowel disease, pharmacogenetics, thalidomide, thiopurines",
author = "Marianna Lucaf{\`o} and Raffaella Franca and Davide Selvestrel and Debora Curci and Letizia Pugnetti and Giuliana Decorti and Gabriele Stocco",
year = "2018",
month = "12",
day = "2",
doi = "10.1080/17425255.2018.1551876",
language = "English",
volume = "14",
pages = "1209--1223",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

TY - JOUR

T1 - Pharmacogenetics of treatments for inflammatory bowel disease

AU - Lucafò, Marianna

AU - Franca, Raffaella

AU - Selvestrel, Davide

AU - Curci, Debora

AU - Pugnetti, Letizia

AU - Decorti, Giuliana

AU - Stocco, Gabriele

PY - 2018/12/2

Y1 - 2018/12/2

N2 - Introduction: Inflammatory bowel disease is a chronic inflammation of the gut whose pathogenesis is still unclear. Although no curative therapy is currently available, a number of drugs are used in induction and maintenance therapy; however, for most of these drugs, a high inter-individual variability in response is observed. Among the factors of this variability, genetics plays an important role. Areas covered: This review summarizes the results of pharmacogenetic studies, considering the most important drugs used and in particular aminosalycilates, glucocorticoids, thiopurines, monoclonal antibodies and thalidomide. Most studies used a candidate gene approach, even if significant breakthroughs have been obtained recently from applying genome-wide studies. When available, also investigations considering epigenetics and pharmacogenetic dosing guidelines have been included. Expert opinion: Only for thiopurines, genetic markers identified as predictors of efficacy or adverse events have allowed the development of dosing guidelines. For the other drugs, encouraging results are available and great expectations rely on the study of epigenetics and integration with pharmacokinetic information, especially useful for biologics. However, to improve therapy of IBD patients with these drugs, for implementation in the clinics of pharmacogenetics, informatic clinical decision support systems and training about pharmacogenetics of health providers are needed.

AB - Introduction: Inflammatory bowel disease is a chronic inflammation of the gut whose pathogenesis is still unclear. Although no curative therapy is currently available, a number of drugs are used in induction and maintenance therapy; however, for most of these drugs, a high inter-individual variability in response is observed. Among the factors of this variability, genetics plays an important role. Areas covered: This review summarizes the results of pharmacogenetic studies, considering the most important drugs used and in particular aminosalycilates, glucocorticoids, thiopurines, monoclonal antibodies and thalidomide. Most studies used a candidate gene approach, even if significant breakthroughs have been obtained recently from applying genome-wide studies. When available, also investigations considering epigenetics and pharmacogenetic dosing guidelines have been included. Expert opinion: Only for thiopurines, genetic markers identified as predictors of efficacy or adverse events have allowed the development of dosing guidelines. For the other drugs, encouraging results are available and great expectations rely on the study of epigenetics and integration with pharmacokinetic information, especially useful for biologics. However, to improve therapy of IBD patients with these drugs, for implementation in the clinics of pharmacogenetics, informatic clinical decision support systems and training about pharmacogenetics of health providers are needed.

KW - Biologics

KW - glucocorticoids

KW - inflammatory bowel disease

KW - pharmacogenetics

KW - thalidomide

KW - thiopurines

UR - http://www.scopus.com/inward/record.url?scp=85058247070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058247070&partnerID=8YFLogxK

U2 - 10.1080/17425255.2018.1551876

DO - 10.1080/17425255.2018.1551876

M3 - Review article

VL - 14

SP - 1209

EP - 1223

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 12

ER -